Key facts
- Notable investors include Tech Incubator Program for Startup, Genaxis (Korea).
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Orand Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Orand Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orand Bio
Developer of biomaterial-based medical devices and regenerative devices designed for treatment of damaged organs and tissues. The company combines biomaterial molding, anti-inflammatory polymers, and tissue regeneration technologies to support kidney recovery, joint repair, bone and periodontal regeneration, and ovarian function restoration, enabling the healthcare market to access targeted therapies that promote healing and restore function.
- Sector
- Healthcare
- HQ
- Uiwang, South Korea
- Founded
- 2024
- Employees
- 4
- Website
- orandbio.com/
- Ownership
- Privately Held (backing)
Orand Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orand Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orand Bio in its N-PORT filings yet. We sweep new filings monthly.